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Abstract : Background & Objectives : Ovarian carcinoma usually has a relatively poor prognosis. A rational approach 
to identify patients, who are likely to benefit from therapy, is urgently needed. Excision repair cross-complemen-
tation group 1 enzyme (ERCC1) has been proposed as a molecular predictor of clinical resistance to platinum-based 
chemotherapy. Steroid hormone receptors are important determinants of prognosis and predictive behavior in 
tumor tissues of several origins. The present study aimed to investigate the expression profile of  ERCC1, ER & 
AR in patients with Ovarian carcinoma and their association with patient outcome. Methods : This is a prospective 
study which included 77 patients with ovarian carcinoma who were treated with platinum based chemotherapy at 
the National Cancer Institute (NCI) in Egypt during the period 7/2016- 7/2018. We evaluated the expression of ER, 
AR, and Excision repair cross-complementation group 1 enzyme (ERCC1) by immunohistochemistry.  Expression 
profiles were compared to clinical, histologic and prognostic factors, the clinical outcome and survival. All pa-
tients received platinum containing chemotherapy regimen. Result : Of the 77 patients with ovarian cancer, 66.2 % 
(51/77) were ERCC1-positive, 49.4 % (38/77) were AR positive & 75.3 % (58/77) were ER positive. Platinum resistance 
was found in eight of the tumors with positive ERCC1 protein expression compared with two among the patients 
with negative tumor staining for ERCC1 (P = 0.643). There was significant association between ER & AR expres-
sion and pathological subtypes (p = 0.004, 0.007) respectively.  There were  no significant association  between ER, 
AR& ERCC1  expression and  PFS (P = 0.447,P = 0.162, P = 0.508 respectively) or OS (P = 0.781, P = 0.569, P = 0.381 
respectively). Based on Cox proportional hazards regression analysis ERCC1, ER &AR were not independent 
factors affecting the prognosis of patients with ovarian carcinoma. Conclusion : These results demonstrate that 
positive ERCC1 expression is not associated with clinical resistance to platinum-based chemotherapy, ERCC1, 
AR& ER expression are not independent factors affecting the prognosis of patients with epithelial ovarian tumors 
and not associated with survival benefits. J. Med. Invest. 67 : 391-398, August, 2020
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INTRODUCTION
 
Ovarian cancer is the leading cause of gynecologic cancer 
death in the United States. Ovarian cancer accounting for 3% of 
cancers among women in the United States, but is the fifth most 
common cause of cancer-related death. It was estimated that 
approximately 22,280  women were diagnosed with ovarian can-
cer in the United States in 2018, and that approximately 14,070 
women died as a result of ovarian cancer in 2018 (1).
According to the National Population-Based Registry Pro-
gram of Egypt 2008-2011, ovarian cancer represent 4.12% with 
crude rate 4.6. It is the 4th most common cancer in females. There 
is a progressive increase in number of incident ovarian cancer 
cases from 2288 in 2013 to 5957 in 2050, approximately 260%of 
2013 incidence. Proportion of ovarian cancer was highest in 
upper Egypt (6.1%), and almost similar in middle Egypt (3.8%), 
and lower Egypt (3.9%)  (2).
Platinum-based chemotherapy drugs are first-line treatments 
for ovarian cancer (3). However, a large number of patients do not 
respond to platinum-based chemotherapy due to drug resistance. 
Previous research shows that the nucleotide excision repair 
(NER) system plays an important role in platinum resistance 
to chemotherapy (4). It repairs platinum-induced DNA damage 
by removing the damaged fragments in the DNA molecule, and 
then synthesizing DNA by DNA polymerase. ERCC1 (excision 
repair cross complementation group 1) is a key gene involved in 
NER.
Endocrine factors play key roles in ovarian cancer develop-
ment, with risk reduction related to multiparity and use of oral 
contraceptives (5,6).
Estrogen regulates growth and differentiation in the normal 
ovaries and has been demonstrated to have mutagenic effects. 
Progesterone, on the other hand, induces apoptosis and decreas-
es cell membrane permeability, leading to decreased invasive po-
tential (7). After menopause, when the estradiol level decreases, 
androgens are still produced and also seem to influence ovarian 
cancer development. Androgens promote cell proliferation, and 
androgen levels are decreased by the use of oral contraceptives (8).
The present study aimed to  investigate the following : 
1-Prognostic value of immunohistochemical expression of 
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ERCC1 and Sex steroid hormone receptors in the tumor 
tissue as regards progression free survival and overall 
survival.




A total of 77 patients diagnosed with EOC were recruited 
between July 2016 and July 2018 in National Cancer Institute 
(Egypt). The median age at diagnosis was 53 years, ranged 
between 18–74 years. As presented in (Table 1), The tumors 
were classified according to the International Federation of Gy-
necology and Obstetrics classification system, with 16 (20.8%) 
samples classified as stage IA,  9 (11.7%) as stage IB, 8 (10.4%) 
as stage II, 19 (24.7%) as stage III and 25 (32.5%) as stage IV. 
The pathological types of the tumor samples were as follows : 56 
(72.7%) Serous carcinoma samples (9 low G (G1), 7 intermediate 
(G2), 40 high G (G3)), 5 (6.5%) mucinous carcinoma, 12 (15.6%) 
endometrium cancer and 2 clear cell carcinoma, 2 transitional 
carcinoma. 67 (87%). Optimal radical surgery (PAH-BSO) was 
done in 67 patients (87%), while conservative surgery was done 
for 9 patients (11.6%) including 7 patients unilateral salpingoo-
phrectomy (9%), 2 patients excised ovarian mass. Peritoneal 
biopsy was performed in 1 patients.
66 patients (85.7%) received systemic platinum-based com-
bination chemotherapy, following the surgical procedure, 37 
(56.06%) patients received systemic chemotherapy as adju-
vant treatment, 14 (21.21%) received as neo-adjuvant and 15 
(22.7%) patients received systemic chemotherapy as adjuvant 
and neoadjuvant.
48 patients (72.2%) received 6 courses of chemotherapy or 
more.
Chemotherapy regimens consisted of 175 mg/m2 taxol plus car-
boplatin calculated at AUC 5–6  every  3 weeks  for  6–8 cycles or 
cycle every week for 18 weeks with AUC 2-3.
Most of patients (n = 37) (57.8%) received carboplatin with 
AUC 5-6 every 3 weeks and 27 (42.2%) patients received carbo-
platin weekly with AUC 2-3.
Ethical approval for the study was granted by the Cairo Uni-
versity ethics committee (Egypt), and all patients had given their 
written informed consent to participate in the study.
Immunohistochemical analysis
Tumor specimens were harvested from 77 patients prior to 
receiving platinum-based treatment.
1.Paraffin sections were made at 4 microns thickness and 
mounted on positive charged slides.  
2.Immunostaining was done for all cases using Automated 
BenchMark ULTRA IHC/ISH system, and the following 
steps occurred automatically :  
•Deparaffinization by using the EZ-prep solution.
•Cell conditioning (standard cell conditioning CC1) for 80 
minutes.
•Antigen retrieval using reaction buffer (PH 7.4-7.8).
•Application of 100µ of each of the ready-to-use monoclonal 
antibodies used in the study under specific incubation tem-
perature and time for each (Table 2).
•Application of Diaminobenzidine (DAB) as a chromogen 
(NexES Ultra View DAB Detection Kit).
•Counterstaining with Hematoxylin II for 8 minutes. 
•Post counter staining with bluing reagent for 4 minutes.
3.Slides were extracted and arranged in racks.  
4.Slides were washed in tap water and soap for 5 minutes and 
then dehydrated in the ascending grades of alcohol for 5 
minutes in each container. 
5.Slides were cleared in Xylene, and then cover slips were 
applied.
Chemotherapy outcome
Clinical curative effect was assessed by routine gynecological 
examination, imaging analysis (color ultrasound, computed 
tomography, magnetic resonance imaging or positron emission 
tomography-computed tomography for abdominal or pelvic re-
gions) and detection of serum carbohydrate antigen (CA)-125 
levels. No recurrence at 6 months post-chemotherapy was re-
ferred to as ‘clinically sensitive’ and included normal serum 
CA-125 levels, no new lesions, or the original residual lesions 
Table 1.　Clinicopathological data of 77 patients with EOC 
Characteristics Numbers Percentage Valid percent
Age
= < 53 42 54.5
> 53 35 45.5
SA (n = 63)
< 1.8 28 36.4 44.4
> = 1.8 35 45.5 55.6
BMI (n = 62)
< 30 26 33.8 41.9
> = 30 36 46.8 58.1
CA 125 (n = 67)
0-35 12 15.6 17.9







I, II 33 42.9
III, IV 44 57.1







Pleural effusin (M1a) 5 6.5 20.0
Liver (HFLs) 10 13.0 40.0
Pulmonary nodules 4 5.2 16.0
Splenic focal lesions 4 5.2 16.0
Anterior abdominal wall 2 2.6 8.0



















SA : Surface area, BMI : Body mass index, ER : Estrogen receptor, 
AR : Androgen receptor, ERCC1 : Excision repair cross-comple-
mentation group 1
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had decreased in size or disappeared as identified by pelvic and 
imaging examination. By contrast, disease progression during 
chemotherapy, a continual increase in serum CA-125 levels or 
the appearance of new lesions identified by imaging at 6 months 
post-chemotherapy was recognized as ‘clinical resistance’.
Follow-up
The final follow-up occurred on July 2019. The median follow 
up period was 22.8 months (range, 1.4 – 38.5 months). Disease 
PFS was described as the time from ovarian cancer surgery  or 
the time from start neoadjuvant chemotherapy to disease re-
currence or mortality, whichever came first. The time between 
surgery or start treatment  and mortality or the end of follow-up 
was described as the overall survival time (OS).
Statistical analysis
Statistical analysis was done using IBM SPSS® Statistics 
version 22 (IBM® Corp., Armonk, NY, USA). Numerical data 
were expressed as mean and standard deviation or median 
and range as appropriate. Qualitative data were expressed as 
frequency and percentage. Pearson’s Chi-square test or Fisher’s 
exact test was used to examine the relation between qualitative 
variables. For not normally distributed quantitative data, com-
parison between two groups was done using Mann-Whitney test 
(non parametric t-test). Survival analysis was done using Ka-
plan-Meier method and comparison between two survival curves 
was done using log-rank test. Multivariate analysis was done 
using Cox-regression method for the factors affecting survival on 
univariate analysis. Hazard ratio (HR) with it 95% confidence 
interval (CI) were used for risk estimation. All tests were two-
tailed. A p-value < 0.05 was considered significant.
RESULTS
Expression of ERCC1 and Relation to Outcome
Brown-yellow granules were observed in the majority of 
tumor cell cytoplasm and nuclei, and corresponded with positive 
ERCC1 expression (Fig. 1). Immunohistochemistry identified 
that 51/77 specimens (66.2%) were ERCC1 positive.
As presented in (Table 3), no significant association was iden-
tified between ERCC1 expression and age (P = 0.930), patho-
logical type (P = 0.482), cell differentiation (P = 0.461), clinical 
stage (P = 0.316) and ER expression (P = 0.056) or AR expression 
(P = 0.127)
While there was significant association between ERCC1 
expression and elevated serum level of CA 125 at the time of 
diagnosis (P = 0.046). Also, presence of omental deposits was 
significantly correlated with the positive ERCC1 expression in 
tumor tissue (P = 0.022)
As presented in (Table 4) (Fig.2), the number of resistant cases 
with positive ERCC1 expression (8/10 ; 80%) was  not significantly 
greater than the number of sensitive cases with positive ERCC1 
expression (41/63 ; 65.1%) (P = 0.351). For the 77 EOC cases, there 
Table 2.　List of used immunohistochemical markers 





AR (N-20) Sc-816Rabbit polyclonal
Santa Cruz 
Biotechnology 42°C 32 Nuclear
Prostatic 
carcinoma
ERCC-1 8F1Mouse monoclonal Gene Tex 37°C 32 Nuclear Tonsil
ER SP1Rabbit monoclonal Roche 37°C 36 Nuclear Breast 
Figure 1.　Positive reaction to ERCC1 in almost all tumor cells, both 
cytoplasmic and nuclear (X10).
Table 3.　Correlation between ERCC1 expression and clinical 
pathological  features.
Clinical feature n negative positive p-value
Age, years 0.930
= < 53 42 14 28
> 53 35 12 23
Stage 0.316
IA 16 9 7
IB 9 3 6
II 8 2 6
III 19 5 14
IV 25 7 18
0.164
I,II 33 14 19
III,IV 44 12 32
Pathological  subtypes 0.482
serous 56 20 36
endometrioid 12 2 10
mucinous 5 1 4
Grade 0.461
GI 12 5 7
GII 19 8 11
GIII 46 13 33
ER 0.056
negative 19 3 16
positive 58 23 35
AR 0.127
negative 39 10 29
positive 38 16 22
CA 125 0.046
0-35 12 1 11
> 35 55 21 34
Omentum 0.022
absent 52 22 30
present 25 4 21
ER : Estrogen receptor, AR : Androgen receptor, ERCC1 : Excision 
repair cross-complementation group 1
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was no significant difference in PFS and median OS between 
patients with positive ERCC1 expression and patients with neg-
ative expression (OS, P = 0.381 ; PFS, P = 0.508) (Fig. 3).
Expression of Sex Steroid Hormone Receptors and Relation to 
Outcome
The expression and the prognostic value were first assessed 
individually for each marker, with ER positivity detected in 
58/77 (75.3%) (Fig 4) and AR positivity detected in 38/77 (49.4%) 
(Fig 5).
The representation of stage, grade, age at diagnosis, histology 
and ERCC1 expression in relation to receptor status is outlined 
in (Table 5). No  significant  association was identified between 
AR expression and  the clinical pathological features ---) age 
(P = 0.209), clinicl stage (P = 0.236), pathological subtypes 
(P = 0.318), pathological grade (P = 0.795), ERCC 1 expression 
(P = 0.127).
There is a significant association between AR expression and 
age (P = 0.050), ER expression (P = 0.004) and  body surface area 
> = 1.8 (P = 0.028)
ER positivity was not significant association was identified 
between ER expression and  the clinical pathological features 
---) age (P = 0.847), clinicl stage (P = 0.815), pathological grade 
(P = 0.867), and border significant with ERCC 1 expression 
(P = 0.056).
There is a significant association between ER expression and 
pathological subtypes (P = 0.007), AR expression (P = 0.004), 
HB > = 10 (P = 0.026) and body surface area > = 1.8 (P = 0.049) 
(Table 6).




N (n = 24)(32.9%) 22 (34.9%) 2 (20%)
P (n = 49)(67.1%) 41 (65.1%) 8 (80%)
ERCC1 : Excision repair cross-complementation group 1
Figure 2.　Correlation between ERCC1 expression and platinum 
sensitivity.
Figure 3.　OS and PFS of patients with positive expression of 
ERCC1 vs. those with negative.
Figure 4.　Moderate diffuse positive nuclear reaction to ER in most 
of tumor cells (X10).
Figure 5.　Positive reaction to AR in some tumor cells (X10).
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Expression of either ER or AR  was not associated with im-
proved PFS (P = 0.447, P = 0.162 respectively) (Fig 6) and OS 
(P = 0.781, P = 0.569 respectively) (Fig 7).
Table 5.　Correlation between AR expression and clinical pathologi-
cal features.
Clinical feature n negative positive p-value
Age, years 0.050
= < 53 42 17 25
> 53 35 22 13
SA 0.028
< 1.8 28 19 9
> = 1.8 35 14 21
Stage 0.236
IA 16 7 9
IB 9 4 5
II 8 2 6
III 19 9 10
IV 25 17 8
0.087
I-II 33 13 20
II-IV 44 26 18
Pathological  subtypes 0.318
serous 56 25 31
endometrioid 12 8 4
mucinous 5 3 2
Grade 0.795
GI 12 5 7
GII 19 10 9
GIII 46 24 22
ER 0.004
negative 19 15 4
positive 58 24 34
ERCC1 0.127
negative 26 10 16
positive 51 29 22
SA : Surface area, ER : Estrogen receptor, AR : Androgen recep-
tor, ERCC1 : Excision repair cross-complementation group 1
Table 6.　Correlation  between ER expression and clinical pathologi-
cal features.
Clinical feature n negative positive p-value
Age, years 0.847
= < 53 42 10 32
> 53 35 9 26
SA 0.049
<1.8 28 11 17
>=1.8 35 6 29
Stage 0.815
IA 16 5 11
IB 9 2 7
II 8 1 7
III 19 6 13
IV 25 5 20
I-II 33 8 25 0.939
III-IV 44 11 33
Pathological  subtypes 0.007
serous 56 9 47
endometrioid 12 3 9
mucinous 5 4 1
Grade 0.867
GI 12 2 10
GII 19 5 14
GIII 46 12 34
AR 0.004
negative 39 15 24
positive 38 4 34
ERCC1 0.056
negative 26 3 23
positive 51 16 35
SA : Surface area, ER : Estrogen receptor, AR : Androgen recep-
tor, ERCC1 : Excision repair cross-complementation group 1
Figure 6.　PFS  of  patients with positive expression  of AR or ER vs. 
those with negative.
Figure 7.　OS  of  patients with positive expression  of AR  or  ER vs. 
those with negative.
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ERCC1 expression, ER expression, AR expression, peritoneal 
deposits and platinum sensitivity. As presented in (Table 7), 
age, platinum sensitivity and received adjuvant chemotherapy 
were identified as independent factors significantly affecting the 
prognosis of patients (P = 0.048, P < 0.001 and P = 0.020, respec-
tively), while  other factors did not significantly affect prognosis.
 
Independent risk factors for patient survival time : 
Cox proportional hazards regression was used to analyze  pos-
sible risk factors, including age, histopathological type, degree of 
cancer cell differentiation, clinical stage, type of surgery and Cox 
regression analysis demonstrated that ERCC1 expression level, 
ER or AR expression were not an independent prognostic factor 
for the survival time of patients with EOC.
 
DISCUSSION
Chemotherapy drug resistance is a major factor restricting the 
improvement of patient survival rates, with 20–30% of patients 
with EOC undergoing primary platinum-resistance ; however, 
80% of patients are likely to eventually encounter resistance 
(9,10). With the rapid development of pharmacogenomics and 
molecular biology, the mechanism of cisplatin resistance is close-
ly associated with NER (11). In DNA repair, ERCC1 is a key 
gene of the NER pathway due to its binding with DNA repair 
endonuclease ERCC1-xeroderma pigmentosum group F (XPF) 
(12,13).
A number of studies have examined the association between 
ERCC1 expression (14-18) and clinical outcomes including re-
sponse to platinum-based therapy, PFS and OS in patients with 
EOC (19). The outcomes of these studies were discriminative, 
ranging from increased rate of platinum resistance (22), worse 
PFS and overall OS (20-22), similar PFS (23-26), to similar OS 
(20-23). In our current study, we were unable to confirm any 
statistically significant association between ERCC1 expression 
and resistance to platinum-based chemotherapy. PFS and OS 
did not significantly differ between the positive and negative 
ERCC1 expression.
A previous meta-analysis evaluated whether response to 
platinum-based chemotherapy was associated with ERCC1 
expression in patients with ovarian cancer (24). It was observed 
that patients with negative ERCC1 expression had a significant-
ly greater response to platinum-based chemotherapy compared 
with patients with positive ERCC1 expression (24), indicating 
that ERCC1 protein expression status is correlated with re-
sponse to platinum-based chemotherapy in ovarian cancer. 
Zhao et al. (25) identified a negative correlation between ERCC1 
expression and clinical chemosensitivity in EOC.
Stadlmann et al. analyzed 80 samples of ovarian cancer uti-
lizing 8F-1 antibody for immunohistochemy and found low 
overall ERCC1 expression (20.3%) and no association between 
protein expression and platinum responsiveness (p = 0.21) (16), 
which correlates with our results. In a study of Steffensen et 
al., immunohistochemy with the 8F-1 antibody against ERCC1 
was used to examine 100 tumor specimens : 45% of specimens 
were positive, which was associated with a significantly poorer 
response to platinum-based chemotherapy but not with a worse 
OS (15). Lin et al. corroborated these findings by demonstrating 
that low ERCC1 protein expression was significantly associated 
with drug sensitivity in 63 patients (26).
In a study of Rubatt et al. (27), in which patients who partic-
ipated in GOG-172 and GOG-182 trials and provided tumor 
samples for translational research were included, 27% of tumors 
were ERCC1-positive. ERCC1 expression was not associated 
with clinical characteristics or platinum responsiveness. Women 
Table 7.　Univariate analysis for survival time.
95% CI for Exp (B)
B SE Wald df P-value Exp (B) Lower Upper
Age.53 .365 .380 .923 1 .337 1.440 .684 3.031
Stage(III, IV vs I,II) .822 .419 3.854 1 .050 2.276 1.001 5.172
Surgery (other vs PAH+BSO) .862 .462 3.477 1 .062 2.368 .957 5.861
Histopatholoy 1.413 2 .493
Path(serous vs mucinous) .745 1.022 .531 1 .466 2.106 .284 15.613
Path(Endometrod vs mucinous) .137 1.156 .014 1 .905 1.147 .119 11.054
Grade: 2.330 2 .312
Grade(1 vs III) -1.130 .746 2.295 1 .130 .323 .075 1.394
Grade(II vs III) -.193 .444 .189 1 .664 .824 .345 1.970
Peritoneal involvement 1.208 .406 8.841 1 .003 3.347 1.509 7.420
ERCC1 expression .276 .419 .434 1 .510 1.318 .580 2.996
ER.AR expression: 2.555 2 .279
ER.AR(either vs both +ve) .063 .450 .019 1 .889 1.065 .440 2.575
ER.AR (Both –ve vs both +ve) .698 .466 2.242 1 .134 2.011 .806 5.017
AR (-ve vs +ve) .535 .387 1.904 1 .168 1.707 .799 3.646
ER .317 .419 .571 1 .450 1.373 .603 3.123
Platinum sensitivty 2.773 .471 34.658 1 < 0.001 16.005 6.358 40.290
Adj.cth .906 .388 5.452 1 .020 2.475 1.157 5.297
CI : confidence interval ; SE : standard error, df : degrees of freedom, ER : Estrogen receptor, AR : Androgen receptor, ERCC1 : Exci-
sion repair cross-complementation group 1, PAH-BSO : Pan abdominal hysterectomy bilateral salpingoophorectomy 
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with ERCC1-positive versus negative tumors had similar 
median PFS (17.9 months versus 17.5 months, respectively, 
p = 0.59), median OS (52 months versus 47 months, respective-
ly, p = 0.30), risk of disease progression [adjusted hazard ratio 
(HR) = 0.90, 95%CI = 0.71-1.15, p = 0.41), and risk of death (ad-
justed HR = 0.81, 95% CI = 0.61-1.07, p = 0.14)
However, Muallem et al. (28) demonstrated that there were 
no significant differences in the PFS between patients with low, 
intermediate and high H-scores for ERCC1 expression.
The prognostic value of sex steroid hormone receptor expres-
sion in ovarian cancer is not fully defined. In this study, we can 
however demonstrate that expression of ER and AR  not predicts 
PFS and OS.
In the present study, no information on use of endocrine 
treatment was available, precluding analyses of possible effects 
of endocrine treatment on the findings reported. However, endo-
crine treatment is not standard in ovarian cancer and is unlikely 
to have been administered to the study cohort to such an extent 
that it has influenced the results (29,30).
The finding that aromatase inhibition appears slightly more 
effective than tamoxifen in ovarian cancer likely reflects the 
more efficient hormone inhibition of aromatase inhibitors. In 
support of this notion, epidemiological studies indicate that 
reduced circulating levels of androgens decrease the risk of 
developing ovarian cancer, but clinical studies have shown only 
limited effects of androgen deprivation (32,34,35). 
The presence and prognostic value of AR expression in ovari-
an cancer vary in different studies, but increased AR expression 
seems to generally be associated with a favorable prognosis 
(29,31,33), contrary to the results in the present study.
Zhaojun, et al., (2017) who investigated the correlation between 
ER expression and epithelial ovarian cancer prognosis in thir-
ty-five studies with a total of 5824 patients were included, and 
demonstrated that the expression of ER, especially ER α, was 
a positive predictor of overall survival among epithelial ovarian 
cancer patients (36), contrary to the results in the present study.
In conclusion, the present study demonstrated that high 
ERCC1 expression in patients with EOC was not associated with 
resistance to platinum-based chemotherapy or with survival 
time. In addition, it was also observed that ERCC1 protein ex-
pression was not an independent  factor affecting the prognosis 
of patients. We demonstrate a prognostic role of PR and AR ex-
pression in ovarian cancer, with independent effects on PFS and 
OS and the best outcome for patients whose tumors displayed 
coexpression of ER and AR.
 Further studies with larger sample sizes and improved study 
designs are required to investigate whether or not ERCC1 may 
function as a predictor for chemotherapy against EOC.
And our data define a basis for further evaluation of the role 
of sex steroid hormone receptors, and in the future possibly 
endocrine treatment, in ovarian cancer and support that such 
studies may be subtype specific to comprehensively evaluate the 
potential clinical benefit.
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